Background {#Sec1}
==========

The species of the *Escherichia* genus is heterogeneous, and this genus includes both commensal and pathogenic bacteria. Although only some *E. coli* are pathological species, they cause infections in various organs, such as the urinary tract, biliary system, and central nervous system, ranging from spontaneously resolving cystitis to life-threatening sepsis syndrome in humans of all ages \[[@CR1]\]. Increasing antibiotic resistance results in increased mortality and morbidity, enhances transmission of resistant bacteria, and increases health expenses \[[@CR2]\]. The emergence of MDR *E. coli* is becoming a global concern, with particular emphasis on *E. coli* sequence type ST131, which is increasingly reported in urinary tract infections (UTIs). In 2008, *E. coli* ST131 was identified as a major clone associated with the spread of CTX-M-15 ESBL resistance \[[@CR3]--[@CR5]\]. Thereafter, *E. coli* ST131 was also strongly associated with fluoroquinolone resistance and co-resistance to aminoglycosides and trimethoprim--sulfamethoxazole (TMP--SMZ) \[[@CR6]--[@CR8]\]. Current strategies to monitor antibiotic resistance in bacteria mainly rely on examining resistance in pathogenic organisms \[[@CR9]\]. However, commensal bacteria, an important reservoir of antibiotic resistance genes, facilitate the spread of such genes to pathogenic bacterial strains \[[@CR10], [@CR11]\]. Humans, companion and noncompanion animals, and foods are established reservoirs of the ST131 *E. coli* clone \[[@CR12]\]. Few studies have investigated fecal carriage of MDR *E. coli* by community children. Therefore, the objective of the study was to investigate the fecal carriage of MDR *E. coli* and ST131 *E. coli* by community children in Southern Taiwan.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

In this prospective study, children aged 0--18 years who were admitted to the Pediatric Department of Kaohsiung Veterans General Hospital from October 2013 to September 2014 because of mild febrile illnesses, namely acute respiratory, gastroenteritis, or skin and soft tissue infection, and underwent regular examinations were enrolled. Exclusion criteria were any history of antibiotic treatment or hospitalization in the 3 months before specimen collection and a history of underlying diseases. The study was approved by the Ethics Committee of the Kaohsiung Veterans General Hospital (reference number VGHKS16-CT2--04). All participants (their parent or legal guardian in the case of children aged less than 16 years) provided informed consent. Stool samples were obtained as soon as it was available after admission. All of them were obtained within 3 days of admission \[[@CR13]\].

Microbiological laboratory procedures {#Sec4}
-------------------------------------

### Screening for *E. coli* strains in stool samples {#Sec5}

Each stool sample was spread on a CHROMagar™ ECC plate (CHROMagar, Paris, France), which is efficient for the simultaneous enumeration of *E. coli* \[[@CR14]\] and incubated at 37 °C for 24 h; *E. coli* strains appeared as blue colonies. A blue colony was picked \[[@CR14]\] and added to 1 mL of sterilized Luria--Bertani medium for serial dilution. A 100-μL suspension was subsequently spread on the CHROMagar™ ECC plate again to identify the *E. coli* colonies presenting the blue color; 1 colony was selected for further analysis.

### Antimicrobial susceptibility testing {#Sec6}

The selected *E. coli* colony was subjected to antimicrobial susceptibility testing using the Vitek 2 automated system (Vitek AMS; bioMerieux Vitek Systems Inc., Hazelwood, MO, USA) with ID-GN and AST-N277 cards (Durham, NC, USA). The ASTN277 card was used to investigate ESBL production and antimicrobial susceptibility. The breakpoints of antimicrobial agents were determined according to Clinical and Laboratory Standards Institute standards \[[@CR15]\]. Each panel had six wells containing cefepime (1.0 μg/mL), cefotaxime (0.5 μg/mL), and ceftazidime (0.5 μg/mL) alone and in combination with clavulanic acid (10, 4, and 4 μg/mL, respectively). The proportional reduction in growth in the wells containing cephalosporin + clavulanic acid compared with that in the wells containing cephalosporin alone was considered indicative of ESBL production. In this study, possible ESBL producers were screened using the M100-S19 (2009) breakpoints for the entire study period (Additional file [1](#MOESM1){ref-type="media"}).

MDR was defined as acquired nonsusceptibility to at least 1 agent in 3 or more antimicrobial categories, namely β-lactam or β-lactamase inhibitors (ampicillin and amoxicillin--clavunate), cephalosporins (flormoxef, cefazolin, cefuroxime, cefoxitin, cefotaxime, cefatazidime, and cefpirome), carbapenem (ertapenem and imipenem), aminoglycosides (gentamicin and amikacin), fluoroquinolones (ciprofloxacin and moxifloxacin), tigecycline, colistin, and TMP--SMZ \[[@CR16]\].

### Detection of O25b--ST131, multilocus sequence typing, and blaCTX-M gene groups {#Sec7}

Polymerase chain reaction was performed as previously described \[[@CR17]\] to screen for the O25b serotype by using the primers rfb.1bis (5′-ATACCGACGACGCCGATCTG-3′) and rfbO25b.r (5′-TGCTATTCATTATGCGCAGC-3′) \[[@CR18], [@CR19]\]. The sequence type was determined through multilocus sequence typing (MLST) by using the Achtman scheme (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>) \[[@CR20]\]. blaCTX-M groups 1, 2, and 9 were detected through multiplex polymerase chain reactions by using specific primers, as previously described \[[@CR21]\]. Furthermore, specific polymerase chain reactions were performed to detect the common group 9 variant (CTX-M-14) and group 1 variant (CTX-M-15) \[[@CR19], [@CR20]\].

Statistical analysis {#Sec8}
--------------------

All statistical analyses were performed using Stata Version 12.1 (StataCorp., College Station, Texas, USA) statistical software package. Categorical data were analyzed using the chi-squared and Fisher exact tests.

Results {#Sec9}
=======

Antimicrobial susceptibility testing {#Sec10}
------------------------------------

Stool samples were collected from 255 children; *E. coli* was cultured from 169 children. Twelve children were excluded because they were receiving antibiotic treatment or were hospitalized in the 3 months before specimen collection. Among 157 *E. coli* isolates, 25.5% (40/157) were susceptible to all tested antibiotics. Furthermore, 70.1% (110/157), 65.6% (103/157), 47.1% (74/157), and 32.5% (51/157) of the isolates were nonsusceptible to ampicillin, amoxicillin--clavunate, TMP--SMZ, and cefazolin, respectively. MDR *E. coli* accounted for 36.9% of all isolates (58/157; Table [1](#Tab1){ref-type="table"}), among which 17.2% (27/157), 14.0% (22/157), and 5.7% (9/157) were nonsusceptible to at least 1 agent in 3, 4, and 5 antimicrobial categories, respectively.Table 1Antimicrobial nonsusceptibility rates of *E. coli* in the stools of community children in Southern TaiwanNon-susceptible rate % (number/total number)TotalMDR *E. coli* (*n* = 58)Non MDR E. coli (*n* = 99)pFlormoxef7.6 (12/157)17.2 (10/58)2.0 (2/99)0.001Ampicillin70.1 (110/157)100.0 (58/58)52.5 (52/99)\< 0.001Amoxicillin/clavunate65.6 (103/157)96.6 (56/58)47.5 (47/99)\< 0.001Cefazolin32.5 (51/157)77.6 (45/58)6.1 (6/99)\< 0.001Cefuroxime22.9 (36/157)55.2 (32/58)4.0 (4/99)\< 0.001Cefuroxime Axetil24.8 (39/157)55.2 (32/58)7.1 (7/99)\< 0.001Cefoxitin15.3 (24/157)37.9 (22/58)2.0 (2/99)\< 0.001Cefotaxime19.6 (31/157)46.6 (27/58)4.0 (4/99)\< 0.001Ceftazidime13.4 (21/157)29.3 (17/58)4.0 (4/99)\< 0.001Cefpirome8.3 (13/157)19.0 (11/58)2.0 (2/99)\< 0.001Ertapenem0.0 (0/157)0.0 (0/58)0.0 (0/99)NAImipenem0.0 (0/157)0.0 (0/58)0.0 (0/99)NAAmikin0.0 (0/157)0.0 (0/58)0.0 (0/99)NAGentamicin22.9 (36/157)60.3 (35/58)1.0 (1/99)\< 0.001Ciprofloxacin18.5 (29/157)43.1 (25/58)4.0 (4/99)\< 0.001Moxifloxacin19.1 (30/157)43.1 (25/58)5.1 (5/99)\< 0.001Tigecycline0.0 (0/157)0.0 (0/58)0.0 (0/99)NAColistin0.6 (1/157)1.7 (1/58)0.0 (0/99)0.190Trimethoprim-sulfamethoxazole47.1 (74/157)84.5 (49/58)25.3 (25/99)\< 0.001*NA* non-appreciable

Thirteen *E. coli* isolates produced ESBL; 11 were MDR *E. coli*. Twenty-nine *E. coli* isolates were nonsusceptible to ciprofloxacin; 25 were MDR *E. coli* (Table [2](#Tab2){ref-type="table"}).Table 2Number of *E. coli* isolates with/without ESBL, susceptible/nonsusceptible ciprofloxacin, O25b, and ST131 in children's stoolST 131Non ST 131O25bNonO25bO25bNonO25bESBL + (*n* = 13)7420ESBL -- (*n* = 144)3314124Cipro R (*n* = 29)61418Cipro S (*n* = 128)4212110

MLST of *E. coli* isolates {#Sec11}
--------------------------

Twenty-six *E. coli* isolates were O25b positive, among which 9 were MDR *E. coli* and 9 were ESBL producers. Among 58 MDR *E. coli* isolates, 7 were O25b--ST131 positive and ESBL producers. Only 1 isolate was positive for O25b--ST131 but was not MDR and did not produce ESBL. Seven isolates with O25b--ST131 positivity were MDR *E. coli*, among which only 1 was susceptible to ciprofloxacin. Furthermore, 1 isolate with O25b--ST131 positivity was not MDR and was susceptible to ciprofloxacin. Compared with the non-ESBL and ciprofloxacin-susceptible groups, the ESBL and ciprofloxacin-nonsusceptible groups had significantly higher rates of O25b--ST131 positivity (4.2% vs 53.9 and 4.70% vs 24.1%, respectively; Table [3](#Tab3){ref-type="table"}).Table 3Rates of *E. coli* ST131 positivity of the ESBL, non-ESBL, ciprofloxacin-nonsusceptible, ciprofloxacin-susceptible, MDR, and non-MDR groupsST131 positive % (number/total number)ESBL n = 1353.6% (7/13)Non-ESBL n = 1444.2% (6/144)P**\<** 0.001Ciprofloxacin non-susceptible (n = 29)24.1% (7/29)Ciprofloxacin susceptible (n = 128)4.7% (6/128)P0.003MDR (n = 58)13.8% (8/58)Non-MDR (n = 99)5.1% (5/99)P0.073

blaCTX-M gene study {#Sec12}
-------------------

Five of the 13 (38.5%) ESBL-producing *E. coli* belonged to blaCTX-M group 9, among which were all CTXM-14, and 4 (80%) were confirmed as ST131. Three O25b ESBL-producing *E. coli* contained the CTX-M group 1 genes that were confirmed to be CTX-M-(3, 15), and they were all ST131 (Table [4](#Tab4){ref-type="table"}).Table 4Number of CTX-M genes detected in O25b and non-O25b ESBL-producing *E. coli* and ESBL-nonproducing *E. coliE. coli*Total number: 157ESBLNon-ESBL13144TypeONOONONo.9417127ST697395131NS697395131NS697395131NS697395131NSNo.00072000041003139553105CTX-M-G100000000000000000011CTX-M-G1 CTX-M-(3,15)00030000000000000001CTX-M-G200000000000000000000CTX-M-G800000000010000000000CTX-M-G9 CTX-M-1400040000011001220005Non-CTX-M-group-(1,2,8,9)0000200002000211755298O, O25b; NO, Non O25b; NS, Non ST.

Discussion {#Sec13}
==========

Antimicrobial resistance in commensal flora is a serious threat because a very highly populated ecosystem, such as the gut, may become a source of additional intestinal infections at a later stage. These infections may subsequently spread to other hosts or transfer genetic resistance elements to other members of the microbiota, including pathogens \[[@CR22]\]. A major public health concern is that with the increasing number of individuals carrying these resistant strains as part of their normal flora, the probability of acquiring clinical infections, either in the community or hospital, increases. Several studies have addressed the prevalence of resistant *E. coli* isolated from the stools of children \[[@CR23]--[@CR38]\] (Table [5](#Tab5){ref-type="table"}). The rates of resistance to first-line antimicrobial agents, namely ampicillin, TMP--SMZ, and first-generation cephalosporins, were 16--100%, 8--100%, and 6--10%, respectively. Furthermore, the rate of resistance to ciprofloxacin was 0--53%, and 2.6--20.3% of *E. coli* were ESBL producers. The aforementioned studies had varied methodologies, study periods, sample sizes, and demographics and should thus be compared cautiously. However, the importance of surveillance of resistant strains must be addressed to achieve a holistic strategy for resistance control.Table 5Summary of 20 studies on the fecal carriage of *E. coli* in community children from different countriesCountry (published years)First authorStudy populationSettingSample sizePrevalence of resistanceHouston, Tex USA (1987) \[[@CR23]\]Reves RRChildrenCross-section, day-care centers79trimethoprim: 37%;\
ampicillin: 70%Bolivia (1998) \[[@CR24]\]Bartoloni Aaged 6--72 monthshealthy children; community-based296Ampicillin: 97%\
TMP/SMX: 94%,\
Cephalothin:10%\
Tetracycline: 92%\
Ciprofloxacin: 0%Shanghai, China (1998) \[[@CR25]\]Zhang XLGroup A: Children of 5--6 years\
Group B: Children of 10--11 yearsA: Nursery school\
B: Primary schoolA: 30\
B: 54A:\
Ampicillin: 93.3%\
Trimethoprim: 100%\
Ciprofloxacin: 43.3%\
B:\
Ampicillin: 100%\
Trimethoprim: 100%\
Ciprofloxacin: 53.7%Mexican (2003) \[[@CR26]\]Zaidi MBhealthy children (1 month to 12 years)day care centers or kindergartens276nalidixic acid: 54%\
ciprofloxacin: 18.5%Bolivia and Peru (2006) \[[@CR27]\]Bartoloni Achildren (aged 6 to 72 months)Health children in four urban area3174Ampicillin: 95%,\
trimethoprim-sulfamethoxazole: 94%\
nalidixic acid: 35%\
gentamicin: 21%\
ciprofloxacin: 18%\
ceftriaxone: 0.1%\
amikacin: 0.1%Germany (2007) \[[@CR28]\]Lietzau Schildren aged 6 months to 4 yearsregular health screening or an acute infection884Ampicillin: 16.6%\
amoxicillineclavulanic acid: 8%\
cotrimoxazole: 8.7%\
Nalidixic acid: 2.0%\
Levofloxacin: 0.4%India (2009) \[[@CR29]\]Seidman JCaged 5--10 yearsprimary school children119Cefazoline: 6.7% (8/119)\
ampicillin: 38.7% (46/119)\
cotrimoxazole: 37.0% (44/119)\
Ciprofloxacin: 12.6% (15/119)\
Cefotaxime: 4.2% (5/119)Senegal (2009) \[[@CR30]\]Ruppé Eaged 1 to 11 yearshealthy children20ESBL-producing: 10%Portugal (2009) \[[@CR31]\]Guimaraes BAged 1 to 14 yearshealthy children112ESBL-positive: 2.7%Vietnam (2012) \[[@CR32]\]Dyar OJchild aged 6--60 monthsrural children (1% with diarrhea)818Ampicillin: 65%\
co-trimoxazole: 68%\
ciprofloxacin: \< 1%Guinea-Bissau (2012) \[[@CR33]\]Isendahl Jchildren \< 5 years of agefever or tachycardia attending a pediatric emergency ward408ESBL-producing E coli: 20.34% (83/408)Sweden (2013) \[[@CR34]\]Kaarme JChildren (range 11--66 months)\
66 monthspreschool313ESBL-producing E coli: 2.6% (8/313)Libyan (2014) \[[@CR35]\]Ahmed SFchildren aged from 3 to 12 yearsDiarrhea attending outpatient clinics134Ampicillin: 78.4%\
Amoxicillin/Clavulanic: 64.2%\
TMP/SMZ: 61.9%\
Cefotaxime: 20.2%\
Ciprofloxacin: 5.2%\
ESBL-producing E coli: 13.4% (18/134)France (2014) \[[@CR36]\]Blanc VChildren (3 and 40 months)Day-care center419ESBL-producing E coli: 6.4%Spain (2014) \[[@CR37]\]Fernández-Reyes Mchildren at the ages of 8, 12, and 16 monthshealthy children in the community125ESBL-producing E coli: 24% of 125 children and 10.7% of the 318 fecal samplesLao People's Democratic Republic (2015) \[[@CR38]\]Stoesser Nchildren ≤6 years of agepreschool childcare facilities397ESBL-producing E coli: 19.65% (78/397)\
Amoxicillin/clavulanate: 10.33% (41/397)\
Co-trimoxazole: 14.61% (58/397)\
Cefotaxime: 19.4% (77/397)\
Ofloxacin: 3.78% (15/397)

The present study is the first to investigate the fecal carriage of MDR *E. coli* in community children in Taiwan. In this study, high rates of nonsusceptibility to commonly used antimicrobial agents, such as ampicillin, amoxicillin + clavulanate, TMP--SMZ, and cefazolin (70, 65.6, 47.1, and 32.5%, respectively) were obtained. The rate of nonsusceptibility to ciprofloxacin was approximately 18.3%. By contrast, the rate of nonsusceptibility to relatively rarely used antibiotics, which could only be prescribed by infection doctors in medical centers in Taiwan, such as imipenem, amikacin, tigecycline, and colistin, was 0%. This phenomenon could be explained by the selective pressure induced by the intensive use of antibiotics commonly used in both humans and nonhumans. Therefore, under the pressure of excessive antibiotic use, genes, such as blaCTX-M, spread amongst different bacterial species and strains through horizontal gene transfer and thus contribute to the rapid dispersal of antibiotic resistance in the community \[[@CR39]\]. In our study, MDR *E. coli* accounted for 36.9% of all isolates. Although this percentage is lower than that reported in Guinea-Bissau \[[@CR33]\], the rates of nonsusceptibility to amoxicillin + clavulanate and ciprofloxacin and of ESBL-producing *E. coli* are still higher than those reported in developed countries \[[@CR28], [@CR36]\].

In our previous study of 111 infants who were hospitalized for UTIs caused by ESBL-producing *E. coli,* O25b--ST131 was identified in 65% of isolates \[[@CR40]\]. Among the 111 patients, 92 isolates belonged to blaCTX-M group 9, and most were CTXM-14. Furthermore, most patients with bacteremia or UTIs were previously healthy and did not exhibit any apparent risk factors, including previous antimicrobial use, hospitalization, neonatal infection, and underlying disease. Only 30% of the infants with UTIs caused by this clone had identifiable risk factors. Our findings support that most drug-resistant *E. coli* infections are community---not hospital---acquired \[[@CR17], [@CR40], [@CR41]\]. Furthermore, we previously evaluated *E. coli* isolated from several rivers in Southern Taiwan and revealed that the most commonly isolated ESBL-producing *E. coli* clonal complexes were ST10 and ST58 and not the major clone ESBL-producing *E. coli* ST131, which causes community-acquired infections both worldwide and in Taiwan \[[@CR42]\]. In contrast, in the present study, ST131 (7/13) was the most common ESBL-producing *E. coli* clone in the stools of children.

In the present study, 13 *E. coli* isolates produced ESBL, of which 11 were MDR *E. coli* and 69% (9/13) were nonsusceptible to ciprofloxacin. These results corroborate the finding that the plasmid-mediated transfer of ESBLs enhances resistance to non-β-lactams, such as quinolones, because plasmids can harbor genes that confer resistance to multiple antibiotic groups \[[@CR43], [@CR44]\]. Furthermore, compared with the non-ESBL and ciprofloxacin-susceptible groups, the ESBL and ciprofloxacin-nonsusceptible groups yielded significantly higher rates of ST131 positivity. The rates of ST131 positivity tended to be higher in the MDR group than in the non-MDR group (13.8% vs 5.1%, *p* = 0.073). These results also demonstrated that the *E. coli* ST131 clone might be associated with antimicrobial resistance.

Our study has some limitations. First, we used a hospital-based design; therefore, our findings are not generalizable to healthy children in the community because of potential selection bias in patient inclusion. Furthermore, the fecal samples in this study were collected within 3 days of hospitalization. Transmission leading to asymptomatic carriage may occur within less than 3 days after hospital admission. Second, to prevent risk factors from affecting the fecal carriage of resistant *E. coli*, patients who received antibiotic treatment or were hospitalized in the 3 months before specimen collection as well as those with underlying diseases were excluded, leading to the possible underestimation of antimicrobial resistance. Third, because the diseases of the enrolled patients were not further classified, we could not determine whether the different diseases affected the fecal carriage and antimicrobial resistance rate of *E. coli*. For example, including children with gastroenteritis may cause bias because the infection may lead to a temporary change in intestinal flora, with a dominance of pathogenic bacteria. In addition, identifying *E. coli* based on the blue color of the CHROMagar™ ECC may cause misidentification because other species, such as *Enterobacter*, *Klebisella*, and *Citrobacter*, also showed a blue color, which may overestimate the prevalence of *E. coli*. However, selecting one isolate per sample for testing may have underestimated the prevalence of *E. coli* in this study.

Conclusion {#Sec14}
==========

This study is the first to report a high rate (37%) of MDR *E. coli* in the stools of community children in Southern Taiwan. Twenty-nine *E. coli* isolates (18.5%) were not susceptible to ciprofloxacin, and approximately 8.3% of *E. coli* produced ESBL. O25b--ST131 (7/13) was the most common ESBL-producing *E. coli* clonal group in the stools of children. These results highlight the importance of establishing an antibiotic stewardship and infection control programs to reduce inappropriate antibiotic use and limit the transmission of MDR *E. coli*.

Additional file
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